Assembly Biosciences Reports Third Quarter 2026 Financial Results and Recent Updates
Initiated Phase 2 clinical study of ABI-6250 in patients with chronic hepatitis delta virus infect
Initiated Phase 2 clinical study of ABI-6250 in patients with chronic hepatitis delta virus infect